Export

You can select particular sections to be included in the output file.
EN
FR

Model List of Essential Medicines

clear Found 118 recommendations for 72 medicines and 27 therapeutic equivalents
Removed medicines and rejected applications are not shown. Show them.
Biological
  1. BCG vaccine General information
    Section
    Immunologicals > Vaccines
    • All vaccines should comply with the WHO requirements for biological substances.
    Indications
    Need for immunization against tuberculosis
  2. Japanese encephalitis vaccine General information
    Section
    Immunologicals > Vaccines
    • All vaccines should comply with the WHO requirements for biological substances.
    Indications
    Need for immunization against certain single viral diseases
  3. Adalimumab General information
    Section
    Immunomodulators for non-malignant disease
    • Parenteral > General injections > SC: 40 mg per 0.8 mL; 40 mg per 0.4 mL; 10 mg per 0.2 mL; 20 mg per 0.4 mL
    Indications
    Axial spondyloarthritis Crohn disease site Rheumatoid arthritis
    Section
    Medicines for juvenile joint diseases
    • Parenteral > General injections > SC: 40 mg per 0.8 mL; 40 mg per 0.4 mL; 10 mg per 0.2 mL; 20 mg per 0.4 mL
    Indications
    Juvenile idiopathic arthritis
  4. Ansuvimab General information
    Section
    Medicines for Ebola virus disease
    • Parenteral > General injections > IV: 400 mg powder for injection
    Indications
    Ebola virus disease
  5. Anti-D immunoglobulin General information
    Section
    Human immunoglobulins
    • Parenteral > General injections > IV: 250 µg in single-dose vial
    • Parenteral > General injections > IM: 250 µg in single-dose vial
    Indications
    Rh incompatibility reaction Maternal care for red cell antibodies
  6. Anti-rabies immunoglobulin General information
    Section
    Human immunoglobulins
    • Parenteral > General injections > IM: 150 IU per mL in vial
    • Parenteral > Locoregional injections > Other: 150 IU per mL in vial
    Indications
    Rabies
  7. Anti-rabies virus monoclonal antibodies General information
    Section
    Immunologicals > Sera, immunoglobulins and monoclonal antibodies
    • Parenteral > Locoregional injections > Intradermal: 40 IU per mL in 1.25 mL vial (human); 40 IU per mL in 2.5 mL vial (human); 100 IU per mL in 2.5 mL vial (human); 300 IU per mL in 10 mL vial (murine); 600 IU per mL in 1 mL vial (murine); 600 IU per mL in 2.5 mL vial (murine); 600 IU per mL in 5 mL vial (murine)
    Indications
    Rabies
  8. Anti-tetanus immunoglobulin General information
    Section
    Human immunoglobulins
    • Parenteral > General injections > IM: 500 IU in vial
    Indications
    Tetanus
  9. Antivenom immunoglobulin General information
    Section
    Immunologicals > Sera, immunoglobulins and monoclonal antibodies
    • Parenteral > General injections > IV:
    Indications
    Harmful effects of or exposure to noxious substances, chiefly nonmedicinal as to source, not elsewhere classified
  10. Asparaginase General information
    Section
    Cytotoxic medicines
    • Parenteral > General injections > unspecified: 10000 IU in vial powder for injection
    Indications
    Lymphoid leukaemia, not elsewhere classified
  11. Atezolizumab General information
    Section
    Immunomodulators
    Indications
    Therapeutic equivalent to pembrolizumab for Other specified malignant neoplasms of bronchus or lung
  12. Atoltivimab + maftivimab + odesivimab General information
    Section
    Medicines for Ebola virus disease
    • Parenteral > General injections > IV: 241.7 mg + 241.7 mg + 241.7 mg in 14.5 mL vial
    Indications
    Ebola virus disease
  13. Beractant General information
    Section
    Medicines administered to the neonate [c]
    • Respiratory > Suspension: 25 mg per mL for intratracheal instillation
    Indications
    Respiratory distress syndrome of newborn
  14. Bevacizumab General information
    Section
    Ophthalmological preparations > Anti-vascular endothelial growth factor (VEGF) preparations
    • Parenteral > Locoregional injections > Intravitreal: 25 mg per mL
    Indications
    Age related macular degeneration
  15. Cemiplimab General information
    Section
    Immunomodulators
    Indications
    Therapeutic equivalent to pembrolizumab for Other specified malignant neoplasms of bronchus or lung
  16. Certolizumab pegol General information
    Section
    Immunomodulators for non-malignant disease
    Indications
    Therapeutic equivalent to adalimumab for Axial spondyloarthritis Therapeutic equivalent to adalimumab for Crohn disease site Therapeutic equivalent to adalimumab for Rheumatoid arthritis
    Section
    Medicines for juvenile joint diseases
    Indications
    Therapeutic equivalent to adalimumab for Juvenile idiopathic arthritis
  17. Cholera vaccine General information
    Section
    Immunologicals > Vaccines
    • All vaccines should comply with the WHO requirements for biological substances.
    Indications
    Need for immunization against cholera alone
  18. Coagulation factor IX complex General information
    Section
    Coagulation factors
    Indications
    Therapeutic equivalent to coagulation factor IX, plasma-derived for Coagulation defects, purpura or other haemorrhagic or related conditions Therapeutic equivalent to coagulation factor IX, plasma-derived for Haemophilia B
  19. Coagulation factor IX, plasma-derived General information
    Section
    Coagulation factors
    • Parenteral > General injections > IV: 500 IU in vial powder for injection; 1000 IU in vial powder for injection
    Indications
    Coagulation defects, purpura or other haemorrhagic or related conditions Haemophilia B
  20. Coagulation factor VIII, plasma-derived General information
    Section
    Coagulation factors
    • Parenteral > General injections > IV: 250 IU in vial powder for injection; 500 IU in vial powder for injection; 1000 IU in vial powder for injection
    Indications
    Haemophilia A
  21. Cryoprecipitate (not pathogen-reduced) General information
    Section
    Blood and blood components
    Indications
    Therapeutic equivalent to cryoprecipitate (pathogen-reduced) for Coagulation defects, purpura or other haemorrhagic or related conditions Therapeutic equivalent to cryoprecipitate (pathogen-reduced) for Obstetric haemorrhage
  22. Cryoprecipitate (pathogen-reduced) General information
    Section
    Blood and blood components
    • Injection: frozen liquid in bag or lyophilized powder in vial containing:
    • > 50 IU Factor VIII
    • > 100 IU vWF
    • > 140 mg clottable fibrinogen per unit
    Indications
    Coagulation defects, purpura or other haemorrhagic or related conditions Obstetric haemorrhage
  23. Dalteparin General information
    Section
    Medicines affecting coagulation
    Indications
    Therapeutic equivalent to enoxaparin for Acute ischaemic heart disease Therapeutic equivalent to enoxaparin for Venous thromboembolism
  24. Darbepoetin alfa General information
    Section
    Antianaemia medicines
    Indications
    Therapeutic equivalent to erythropoiesis-stimulating agents for Anaemia due to chronic disease
  25. Dengue vaccine General information
    Section
    Immunologicals > Vaccines
    • All vaccines should comply with the WHO requirements for biological substances.
    Indications
    Need for immunization against certain single viral diseases
  26. Diphtheria antitoxin General information
    Section
    Immunologicals > Sera, immunoglobulins and monoclonal antibodies
    • Parenteral > General injections > IM: 10000 IU in vial; 20000 IU in vial
    Indications
    Need for immunization against diphtheria alone
  27. Diphtheria vaccine General information
    Section
    Immunologicals > Vaccines
    • All vaccines should comply with the WHO requirements for biological substances.
    Indications
    Need for immunization against diphtheria alone
  28. Dulaglutide General information
    Section
    Hypoglycaemic agents
    Indications
    Therapeutic equivalent to semaglutide for Type 2 diabetes mellitus
  29. Emicizumab General information
    Section
    Medicines affecting coagulation
    • Parenteral > General injections > SC: 12 mg per 0.4 mL in vial; 30 mg per mL in mL vial; 60 mg per 0.4 mL in vial; 105 mg per 0.7 mL in vial; 150 mg per mL in vial; 300 mg per 2 mL in vial
    Indications
    Haemophilia A
  30. Enoxaparin General information
    Section
    Medicines affecting coagulation
    • Parenteral > General injections > SC: 20 mg per 0.2 mL in prefilled syringe; 40 mg per 0.4 mL in prefilled syringe; 60 mg per 0.6 mL in prefilled syringe; 80 mg per 0.8 mL in prefilled syringe; 100 mg per 1 mL in prefilled syringe; 120 mg per 0.8 mL in prefilled syringe; 150 mg per 1 mL in prefilled syringe; 150 mg per 1 mL in ampoule; 20 mg per 0.2 mL in ampoule; 40 mg per 0.4 mL in ampoule; 60 mg per 0.6 mL in ampoule; 80 mg per 0.8 mL in ampoule; 100 mg per 1 mL in ampoule; 120 mg per 0.8 mL in ampoule
    Indications
    Acute ischaemic heart disease Venous thromboembolism
  31. Epoetin alfa General information
    Section
    Antianaemia medicines
    Indications
    Therapeutic equivalent to erythropoiesis-stimulating agents for Anaemia due to chronic disease
  32. Epoetin beta General information
    Section
    Antianaemia medicines
    Indications
    Therapeutic equivalent to erythropoiesis-stimulating agents for Anaemia due to chronic disease
  33. Epoetin theta General information
    Section
    Antianaemia medicines
    Indications
    Therapeutic equivalent to erythropoiesis-stimulating agents for Anaemia due to chronic disease
  34. Equine rabies immunoglobulin General information
    Section
    Immunologicals > Sera, immunoglobulins and monoclonal antibodies
    • Parenteral > Locoregional injections > Intradermal: 150 IU per mL in vial; 200 IU per mL in vial; 300 IU per mL in vial; 400 IU per mL in vial
    Indications
    Rabies
  35. Erythropoiesis-stimulating agents General information
    Section
    Antianaemia medicines
    • Parenteral > General injections > unspecified: 1000 IU per 0.5 mL pre-filled syringe; 2000 IU per 0.5 mL pre-filled syringe; 3000 IU per 0.3 mL pre-filled syringe; 4000 IU per 0.4 mL pre-filled syringe; 5000 IU per 0.5 mL pre-filled syringe; 6000 IU per 0.6 mL pre-filled syringe; 8000 IU per 0.8 mL pre-filled syringe; 10000 IU per 1 mL pre-filled syringe; 20000 IU per 0.5 mL pre-filled syringe; 40000 IU per 1 mL pre-filled syringe
    Indications
    Anaemia due to chronic disease
  36. Etanercept General information
    Section
    Immunomodulators for non-malignant disease
    Indications
    Therapeutic equivalent to adalimumab for Axial spondyloarthritis Therapeutic equivalent to adalimumab for Crohn disease site Therapeutic equivalent to adalimumab for Rheumatoid arthritis
    Section
    Medicines for juvenile joint diseases
    Indications
    Therapeutic equivalent to adalimumab for Juvenile idiopathic arthritis
  37. Filgrastim General information
    Section
    Immunomodulators
    • Parenteral > General injections > SC: 120 µg per 0.2 mL in prefilled syringe; 300 µg per 0.5 mL in prefilled syringe; 480 µg per 0.8 mL in prefilled syringe; 300 µg per mL in 1 mL vial; 480 µg per 1.6 mL in 1.6 mL vial
    Indications
    Acquired neutropaenia
  38. Fresh-frozen plasma General information
    Section
    Blood and blood components
    • Parenteral > General injections > IV:
    Indications
    Blood transfusion without reported diagnosis
  39. Golimumab General information
    Section
    Immunomodulators for non-malignant disease
    Indications
    Therapeutic equivalent to adalimumab for Axial spondyloarthritis Therapeutic equivalent to adalimumab for Crohn disease site Therapeutic equivalent to adalimumab for Rheumatoid arthritis
    Section
    Medicines for juvenile joint diseases
    Indications
    Therapeutic equivalent to adalimumab for Juvenile idiopathic arthritis
  40. Haemophilus influenzae type b vaccine General information
    Section
    Immunologicals > Vaccines
    • All vaccines should comply with the WHO requirements for biological substances.
    Indications
    Need for immunization against single bacterial diseases
  41. Hepatitis A vaccine General information
    Section
    Immunologicals > Vaccines
    • All vaccines should comply with the WHO requirements for biological substances.
    Indications
    Need for immunization against viral hepatitis
  42. Hepatitis B vaccine General information
    Section
    Immunologicals > Vaccines
    • All vaccines should comply with the WHO requirements for biological substances.
    Indications
    Need for immunization against viral hepatitis
  43. Human papilloma virus (HPV) vaccine General information
    Section
    Immunologicals > Vaccines
    • All vaccines should comply with the WHO requirements for biological substances.
    Indications
    Need for immunization against certain single viral diseases
  44. Infliximab General information
    Section
    Immunomodulators for non-malignant disease
    Indications
    Therapeutic equivalent to adalimumab for Axial spondyloarthritis Therapeutic equivalent to adalimumab for Crohn disease site Therapeutic equivalent to adalimumab for Rheumatoid arthritis
    Section
    Medicines for juvenile joint diseases
    Indications
    Therapeutic equivalent to adalimumab for Juvenile idiopathic arthritis
  45. Influenza vaccine (seasonal) General information
    Section
    Immunologicals > Vaccines
    • All vaccines should comply with the WHO requirements for biological substances.
    Indications
    Need for immunization against influenza
  46. Insulin (analogue, long-acting) General information
    Section
    Insulins
    • Parenteral > General injections > SC: 100 IU per mL in 3 mL cartridge solution; 100 IU per mL in 3 mL pre-filled pen solution; 100 IU per mL in 10 mL vial solution
    Indications
    Type 2 diabetes mellitus Type 1 diabetes mellitus
  47. Insulin (human, intermediate-acting) General information
    Section
    Insulins
    • Parenteral > General injections > SC: 40 IU per mL in 10 mL vial as compound insulin zinc suspension or isophane insulin; 100 IU per mL in 10 mL vial as compound insulin zinc suspension or isophane insulin; 100 IU per mL in 3 mL cartridge as compound insulin zinc suspension or isophane insulin; 100 IU per mL in 3 mL pre-filled pen as compound insulin zinc suspension or isophane insulin
    Indications
    Type 2 diabetes mellitus Type 1 diabetes mellitus
  48. Insulin (human, short-acting) General information
    Section
    Insulins
    • Parenteral > General injections > SC: 40 IU per mL in 10 mL vial solution; 100 IU per mL in 10 mL vial solution; 100 IU per mL in 3 mL cartridge solution; 100 IU per mL in 3 mL pre-filled pen solution
    Indications
    Type 2 diabetes mellitus Type 1 diabetes mellitus
  49. Insulin degludec General information
    Section
    Insulins
    Indications
    Therapeutic equivalent to insulin (analogue, long-acting) for Type 2 diabetes mellitus Therapeutic equivalent to insulin (analogue, long-acting) for Type 1 diabetes mellitus
  50. Insulin detemir General information
    Section
    Insulins
    Indications
    Therapeutic equivalent to insulin (analogue, long-acting) for Type 2 diabetes mellitus Therapeutic equivalent to insulin (analogue, long-acting) for Type 1 diabetes mellitus
  51. Insulin glargine General information
    Section
    Insulins
    Indications
    Therapeutic equivalent to insulin (analogue, long-acting) for Type 2 diabetes mellitus Therapeutic equivalent to insulin (analogue, long-acting) for Type 1 diabetes mellitus
  52. Liraglutide General information
    Section
    Hypoglycaemic agents
    Indications
    Therapeutic equivalent to semaglutide for Type 2 diabetes mellitus
  53. Measles vaccine General information
    Section
    Immunologicals > Vaccines
    • All vaccines should comply with the WHO requirements for biological substances.
    Indications
    Need for immunization against measles alone
  54. Meningococcal meningitis vaccine General information
    Section
    Immunologicals > Vaccines
    • All vaccines should comply with the WHO requirements for biological substances.
    Indications
    Need for immunization against single bacterial diseases
  55. Methoxy polyethylene glycol-epoetin beta General information
    Section
    Antianaemia medicines
    Indications
    Therapeutic equivalent to erythropoiesis-stimulating agents for Anaemia due to chronic disease
  56. Mumps vaccine General information
    Section
    Immunologicals > Vaccines
    • All vaccines should comply with the WHO requirements for biological substances.
    Indications
    Need for immunization against mumps alone
  57. Nadroparin General information
    Section
    Medicines affecting coagulation
    Indications
    Therapeutic equivalent to enoxaparin for Acute ischaemic heart disease Therapeutic equivalent to enoxaparin for Venous thromboembolism
  58. Nivolumab General information
    Section
    Immunomodulators
    • Parenteral > General injections > IV: 10 mg per mL in 4 mL vial concentrate solution for infusion; 10 mg per mL in 10 mL vial concentrate solution for infusion; 10 mg per mL in 12 mL vial concentrate solution for infusion; 10 mg per mL in 24 mL vial concentrate solution for infusion
    Indications
    Melanoma of skin
  59. Normal immunoglobulin General information
    Section
    Human immunoglobulins
    • Parenteral > General injections > IV: 5% protein solution; 10% protein solution
    • Parenteral > General injections > IM: 16% protein solution
    • Parenteral > General injections > SC: 15% protein solution; 16% protein solution
    Indications
    Primary immunodeficiencies Langerhans cell histiocytosis Mucocutaneous lymph node syndrome
    Section
    Medicines for Guillain-Barré syndrome
    • Parenteral > General injections > IV: 5% protein solution; 10% protein solution
    Indications
    Acute inflammatory demyelinating polyneuropathy
  60. Pegaspargase General information
    Section
    Cytotoxic medicines
    • Parenteral > General injections > IV: 3750 units per 5 mL in vial; 3750 units in vial powder for injection
    Indications
    Lymphoid leukaemia, not elsewhere classified
  61. Pegfilgrastim General information
    Section
    Immunomodulators
    • Parenteral > General injections > SC: 6 mg per 0.6 mL in pre-filled syringe
    Indications
    Acquired neutropaenia
  62. Pembrolizumab General information
    Section
    Immunomodulators
    • Parenteral > General injections > IV: 25 mg per mL in 4 mL vial
    • Parenteral > General injections > IV: 25 mg per mL in 4 mL vial powder for injection
    Indications
    Other specified malignant neoplasms of large intestine Other specified malignant neoplasms of bronchus or lung Therapeutic equivalent to nivolumab for Melanoma of skin
  63. Pertussis vaccine General information
    Section
    Immunologicals > Vaccines
    • All vaccines should comply with the WHO requirements for biological substances.
    Indications
    Need for immunization against pertussis alone
  64. Platelets General information
    Section
    Blood and blood components
    • Parenteral > General injections > IV:
    Indications
    Blood transfusion without reported diagnosis
  65. Pneumococcal vaccine General information
    Section
    Immunologicals > Vaccines
    • All vaccines should comply with the WHO requirements for biological substances.
    Indications
    Need for immunization against single bacterial diseases
  66. Poliomyelitis vaccine General information
    Section
    Immunologicals > Vaccines
    • All vaccines should comply with the WHO requirements for biological substances.
    Indications
    Need for immunization against poliomyelitis
  67. Rabies vaccine General information
    Section
    Immunologicals > Vaccines
    • All vaccines should comply with the WHO requirements for biological substances.
    Indications
    Need for immunization against rabies
  68. Red blood cells General information
    Section
    Blood and blood components
    • Parenteral > General injections > IV:
    Indications
    Blood transfusion without reported diagnosis
  69. Rituximab General information
    Section
    Targeted therapies
    • Parenteral > General injections > IV: 100 mg per 10 mL in 10 mL vial; 500 mg per 50 mL in 50 mL vial
    Indications
    Follicular lymphoma Burkitt lymphoma including Burkitt leukaemia Chronic lymphocytic leukaemia or small lymphocytic lymphoma Diffuse large B-cell lymphoma, not otherwise specified
    Section
    Medicines for multiple sclerosis
    • Parenteral > General injections > IV: 500 mg per 50 mL in 50 mL vial
    Indications
    Multiple sclerosis
  70. Rotavirus vaccine General information
    Section
    Immunologicals > Vaccines
    • All vaccines should comply with the WHO requirements for biological substances.
    Indications
    Need for immunization against certain single viral diseases
  71. Rubella vaccine General information
    Section
    Immunologicals > Vaccines
    • All vaccines should comply with the WHO requirements for biological substances.
    Indications
    Need for immunization against rubella alone
  72. Semaglutide General information
    Section
    Hypoglycaemic agents
    • Parenteral > General injections > SC: 0.68 mg per mL; 1.34 mg per mL; 2.68 mg per mL
    Indications
    Type 2 diabetes mellitus
  73. Tetanus vaccine General information
    Section
    Immunologicals > Vaccines
    • All vaccines should comply with the WHO requirements for biological substances.
    Indications
    Need for immunization against tetanus alone
  74. Tick-borne encephalitis vaccine General information
    Section
    Immunologicals > Vaccines
    • All vaccines should comply with the WHO requirements for biological substances.
    Indications
    Need for immunization against arthropod-borne viral encephalitis
  75. Tirzepatide General information
    Section
    Hypoglycaemic agents
    Indications
    Therapeutic equivalent to semaglutide for Type 2 diabetes mellitus
  76. Trastuzumab General information
    Section
    Targeted therapies
    • Parenteral > General injections > IV: 60 mg in vial powder for injection; 150 mg in vial powder for injection; 440 mg in vial powder for injection
    Indications
    Carcinoma of breast, specialised type
  77. Typhoid vaccine General information
    Section
    Immunologicals > Vaccines
    • All vaccines should comply with the WHO requirements for biological substances.
    Indications
    Need for immunization against typhoid-paratyphoid alone
  78. Ustekinumab General information
    Section
    Dermatological medicines > Medicines affecting skin differentiation and proliferation
    • Parenteral > General injections > SC: 45 mg per 0.5 mL in vial; 45 mg per 0.5 mL in pre-filled syringe; 45 mg per 0.5 mL in pre-filled pen; 90 mg per mL in pre-filled syringe; 90 mg per mL in pre-filled pen
    Indications
    Psoriasis of unspecified type
  79. Varicella vaccine General information
    Section
    Immunologicals > Vaccines
    • All vaccines should comply with the WHO requirements for biological substances.
    Indications
    Need for immunization against certain single viral diseases
  80. Whole blood General information
    Section
    Blood and blood components
    • Parenteral > General injections > IV:
    Indications
    Blood transfusion without reported diagnosis
  81. Yellow fever vaccine General information
    Section
    Immunologicals > Vaccines
    • All vaccines should comply with the WHO requirements for biological substances.
    Indications
    Need for immunization against certain single viral diseases